Refractive change after dorzolamide use in patients with primary open-angle glaucoma and ocular hypertension

Journal of Ocular Pharmacology and Therapeutics

Volumn 17, Issue 6, 2001, Pages 499-504

  Tsai, J C ^a   Chang, H W ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE;

ADULT; AGED; ANTERIOR EYE CHAMBER DEPTH; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EYE REFRACTION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MALE; OPEN ANGLE GLAUCOMA; PROSPECTIVE STUDY; REFRACTION ERROR; TREATMENT OUTCOME;

EID: 0035675547     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/10807680152729185     Document Type: Article

References (12)

1. Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor
2. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans
3. Transient myopia induced by sulfonamides
4. The mechanism of transient myopia induced by sulfonamide therapy
5. Transient myopia associated with vaginal sulfonamide suppositories
6. Diamox®-induced myopia
7. Transient myopia after acetazolamide
8. MK-507 versus sezolamide
9. Four-week safety and efficacy of dorzolamide, a novel, active topical carbonic anhydrase inhibitor
10. Dorzolamide, a topical carbonic anhydrase inhibitor: A two-week dose-response study in patients with glaucoma or ocular hypertension
11. A double-masked, randomized, 1-year study comparing dorzolamide (Trusopt®), timolol, and betaxolol
12. Transient myopia following the use of acetazolamide